# A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance

Source: https://onco.cc/trials/nct07223047/  
OnCo record `nct07223047` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Gemcitabine, Paclitaxel / nab-paclitaxel, Cetuximab in non-small-cell lung cancer and small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.

## Summary

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT07223047 by Bristol-Myers Squibb, with 252 participants planned, started 2025-11-25 and due to reach its primary completion in 2028-10-13. Interventions recorded: BMS-986523, Gemcitabine, Nab-Paclitaxel, Cetuximab, Pembrolizumab. Conditions listed: Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07223047
- Phase: 1/2
- Setting: A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
- Sponsor: Bristol-Myers Squibb
- Enrolled: 252

## Sources

- ClinicalTrials.gov NCT07223047: https://clinicaltrials.gov/study/NCT07223047

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct07223047.json